COVID-19 and Nonalcoholic Fatty Liver Disease

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 15, 2022

Conditions
Covid19NAFLD
Interventions
DIAGNOSTIC_TEST

Th17 cytokine profile

Screening for the components of metabolic syndrome

DIAGNOSTIC_TEST

Screening for the components of metabolic syndrome

Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.

DIAGNOSTIC_TEST

Evaluation of the degree of steatosis

The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.

Trial Locations (1)

10000

University Hospital for Infectious Diseases Zagreb, Zagreb

All Listed Sponsors
lead

University Hospital for Infectious Diseases, Croatia

OTHER

NCT04982328 - COVID-19 and Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter